000 04123nam a22004695i 4500
003 DE-He213
005 20151013141913.0
007 cr nn 008mamaa
008 141010s2015 gw | s |||| 0|eng d
020 _a9783319090757
_9978-3-319-09075-7
024 7 _a10.1007/978-3-319-09075-7
_2doi
050 4 _aHD30.23
072 7 _aKJT
_2bicssc
072 7 _aKJMD
_2bicssc
072 7 _aBUS049000
_2bisacsh
082 0 4 _a658.40301
_223
100 1 _aAntonijevic, Zoran.
_eeditor.
245 1 0 _aOptimization of Pharmaceutical R&D Programs and Portfolios
_h[electronic resource] :
_bDesign and Investment Strategy /
_cedited by Zoran Antonijevic.
260 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2015.
300 _aVIII, 202 p. 38 illus., 24 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aNeed for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development -- Clinical Aspects of Pharmaceutical Portfolio Management -- Drug Development and the Cost of Capital -- Investment Considerations for Pharmaceutical Product Portfolios -- Challenges of Portfolio Management in Pharmaceutical Development -- Impact of Phase 2b Strategies on Optimization of Drug Development Programs -- Using Decision Analysis to Support the Design of Clinical Trials at a Program Level -- Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications -- Maximizing Return on Investment in Phase II Proof-of-Concept Trials -- Portfolio Optimization of Therapies and Their Predictive Biomarkers -- Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.
520 _aVery little has been published on optimization of pharmaceutical portfolios. Moreover, most of the published literature comes from the commercial perspective, where probability of technical success (PoS) is treated as fixed, and not as a consequence of development strategy or design. In this book there is a strong focus on the impact of study design on PoS, and ultimately a portfolio’s value. Design options that are discussed are dose-selection strategies, adaptive design, and enrichment. Some development strategies that are examined are indication sequencing, optimal number of programs, and optimal decision criteria.     This book includes chapters written by authors with very broad backgrounds including financial, clinical, statistical, decision sciences, commercial, and regulatory. Many authors have long held executive positions and have been involved with decision making at a product or at a portfolio level. As such, it is expected that this book will attract a very broad audience, including decision makers in pharmaceutical R&D, commercial, and financial departments. The intended audience also includes portfolio planners and managers, statisticians, decision scientists, and clinicians. Early chapters describe approaches to portfolio optimization from big pharma, and venture capital standpoints, focusing on finances and processes. Later chapters present selected statistical and decision analysis methods for optimizing drug development programs and portfolios. Some methodological chapters are technical; however, with a few exceptions they require a basic knowledge of statistics by a reader. 
650 0 _aEconomics.
650 0 _aMathematical optimization.
650 0 _aStatistics.
650 0 _aOperations research.
650 1 4 _aEconomics/Management Science.
650 2 4 _aOperation Research/Decision Theory.
650 2 4 _aOptimization.
650 2 4 _aStatistics for Life Sciences, Medicine, Health Sciences.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783319090740
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-319-09075-7
912 _aZDB-2-SBE
942 _2ddc
_cEBOOK
999 _c3092
_d3092